文献速递神经肿瘤

SLC10A3 是低级别胶质瘤的预后生物标志物并参与免疫浸润与程序性细胞死亡

SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
PubMed 文献 · World Neurosurg · 2023-08-04

本研究利用公共数据库和生物信息学分析探讨 SLC10A3 与低级别胶质瘤(LGG)的关系。结果显示 SLC10A3 在 LGG 中表达上调,与总生存期(OS)不良相关,并随 WHO 级别升高而增加;SLC10A3 具有诊断和预后价值,是 LGG 的独立预后因素,且与免疫浸润及多种程序性细胞死亡基因特征中度相关。

要点

  • SLC10A3 在 LGG 中表达上调,与总生存期不良相关。
  • SLC10A3 表达随 WHO 级别升高而增加,在 IDH 野生型、1p/19q 非共缺失及星形细胞瘤中更高。
  • SLC10A3 是 LGG 的独立预后因素,列线图对 OS 和 DSS 具有中等准确度预测价值。

核心结论

  • SLC10A3 是 LGG 潜在的诊断和预后生物标志物,可能与物质转运、神经源性信号、免疫浸润和程序性细胞死亡相关。

研究设计与样本

  • 研究利用公共数据库和生物信息学分析 SLC10A3,数据库包括癌症基因组图谱(TCGA)、基因型-组织表达(GTEx)、中国胶质瘤基因组图谱(CGGA)、人类蛋白质图谱(HPA)、GeneCards、cBioPortal、STRING、GEPIA、TIMER、TISIDB 等,分析方法包括 ROC 曲线分析、Kaplan-Meier 分析、Cox 分析、列线图、校准图、GO/KEGG 富集分析、GSEA、ssGSEA 和 Spearman 相关分析。

主要发现

  • SLC10A3 在肾上腺皮质癌、胶质母细胞瘤和 LGG 中表达上调,在肾上腺皮质癌中与良好总生存期(OS)相关,在 LGG 和胶质母细胞瘤中与不良 OS 相关。
  • SLC10A3 表达随 WHO 级别升高而增加,在 IDH 野生型、1p/19q 非共缺失中上调,在星形细胞瘤中更高。
  • SLC10A3 的遗传改变与 LGG 不良无进展生存期相关;SLC10A3 具有诊断和预后价值(OS、DSS 和无进展间期),是 LGG 的独立预后因素。
  • 列线图(WHO 级别、1p/19q 共缺失、年龄和 SLC10A3)对 OS 和 DSS 具有中等准确度预测价值。
  • 功能分析显示 SLC10A3 可能参与 LGG 中多种物质的转运、神经源性信号、免疫反应和程序性细胞死亡;SLC10A3 与 LGG 免疫浸润相关,并与焦亡、溶酶体依赖性细胞死亡、坏死性凋亡、凋亡、铁死亡、碱死亡和自噬依赖性细胞死亡基因特征中度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between SLC10A3 (solute carrier family 10 member 3) and lower grade glioma (LGG) remains unclear. METHODS: We used public databases and bioinformatics analysis to analyze SLC10A3. These included The Cancer Genome Atlas, Genotype-Tissue Expansion, Chinese Glioma Genome Atlas, Human Protein Atlas, GeneCards, cBioPortal, Search Tool for the Retrieval of Interacting Genes/Proteins, Gene Expression Profiling Interactive Analysis, Tumor Immune Estimation Resource, Tumor-Immune System Interaction Database, receiver operating characteristic curve analysis, Kaplan-Meier analysis, Cox analysis, nomograms, calibration plots, gene ontology/Kyoto Encyclopedia of Genes and Genomes enrichment analysis, gene set enrichment analysis, single-sample gene set enrichment analysis, and Spearman's correlation analysis. RESULTS: SLC10A3 was upregulated in adrenocortical carcinoma, glioblastoma, and LGG and was associated with good overall survival (OS) in adrenocortical carcinoma and poor OS in LGG and glioblastoma. SLC10A3 was increased with increased World Health Organization grade, upregulated in isocitrate dehydrogenase-wild type, 1p/19q (chromosome arms 1p and 19q) non-co-deleted, and higher in astrocytoma. Patients with LGG were grouped by the occurrence of the clinical outcome endpoints (i.e., OS, disease-specific survival [DSS], and progression-free interval events). Genetic alterations in SLC10A3 were associated with poor progression-free survival in LGG. Most of clinical characteristics were associated with the SLC10A3 expression level. SLC10A3 with diagnostic and prognostic value (OS, DSS, and progression-free interval) was an independent prognostic factor in LGG. Moreover, Nomograms (WHO grade, 1p/19q codeletion, age and SLC10A3) had moderately accurate predictive for OS and DSS. Functional analysis showed that SLC10A3 might participate in the transport of multiple substances, neurogenic signaling, immune response, and programmed cell death in LGG. SLC10A3 correlated with immune infiltration in LGG and moderately correlated with the gene signature of pyroptosis, lysosome-dependent cell death, necroptosis, apoptosis, ferroptosis, alkaliptosis, and autophagy-dependent cell death. CONCLUSIONS: SLC10A3 is a potential diagnostic and prognostic biomarker for LGG and might be associated with substance transport, neurogenic signaling, immune infiltration, and programmed cell death in LGG.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ma W, Mei P. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma. World Neurosurg. 2023. PMID: 37543196. doi:10.1016/j.wneu.2023.07.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。